ATAI · Insider Trading
AtaiBeckley Inc. Common Stock
Every open-market purchase and sale reported by ATAI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Scott Braunstein | Director | D | −573,881 deriv. | — |
| 2026-09-11 | Michael E. Faerm | Chief Financial Officer | D | −1,560,000 deriv. | — |
| 2026-09-11 | Andrea Heslin Smiley | Director | D | −4,666 | — |
| 2026-09-11 | Anne Nagengast Johnson | Chief Accounting Officer | D | −140,045 | — |
| 2026-09-11 | Robert Hershberg | Director | D | −741,089 deriv. | — |
| 2026-09-11 | Laurent Fischer | Director | D | −430,968 deriv. | — |
| 2026-09-11 | Amir H Kalali | Director | D | −4,666 | — |
| 2026-09-11 | Glenn Frank Short | Chief Scientific Officer | D | −42,333 | — |
| 2026-09-11 | John Francis Hoffman | Director | D | −327,968 deriv. | — |
| 2026-09-11 | Gerd Kochendoerfer | Chief Operating Officer | D | −2,225,000 deriv. | — |
| 2026-09-11 | Kevin James Craig | Chief Medical Officer | D | −8,437 | — |
| 2026-09-11 | Apeiron Investment Group Ltd. | 10%+ Owner | D | −111,513,496 | — |
| 2026-09-11 | Srinivas Rao | See remarks | D | −216,442 | — |
| 2026-09-11 | Sabrina Martucci Johnson | Director | D | −455,968 deriv. | — |
| 2026-09-11 | Christopher Ryan Cave Barrett | See remarks | D | −155,066 | — |
| 2026-07-09 | Robert Hershberg | Director | MIXED | — | −$361.00K |
| 2026-06-29 | Gerd Kochendoerfer | Chief Operating Officer | MIXED | — | −$170.00K |
| 2026-06-29 | Kevin James Craig | Chief Medical Officer | MIXED | — | −$131.21K |
| 2026-06-08 | Christian Angermayer | Director | A | +121,968 deriv. | — |
| 2026-06-08 | Amir H Kalali | Director | A | +121,968 deriv. | — |
| 2026-06-08 | Scott Braunstein | Director | A | +208,063 deriv. | — |
| 2026-06-08 | Andrea Heslin Smiley | Director | A | +121,968 deriv. | — |
| 2026-06-08 | Sabrina Martucci Johnson | Director | A | +121,968 deriv. | — |
| 2026-06-08 | Robert Hershberg | Director | A | +121,968 deriv. | — |
| 2026-06-08 | John Francis Hoffman | Director | A | +121,968 deriv. | — |
| 2026-06-08 | Laurent Fischer | Director | A | +121,968 deriv. | — |
| 2026-04-22 | Kevin James Craig | Chief Medical Officer | MIXED | — | −$143.82K |
| 2026-04-10 | Apeiron Investment Group Ltd. | 10%+ Owner | M | +1,118,464 | +$1.79M |
| 2025-11-26 | Cosmo Feilding-Mellen | Director | MIXED | −30,400 deriv. | — |
| 2025-11-06 | Scott Braunstein | Director | A | +56,818 deriv. | — |
| 2025-11-06 | Cosmo Feilding-Mellen | Director | A | +7,702,990 | — |
| 2025-11-06 | Robert Hershberg | Director | A | +719,121 deriv. | — |
| 2025-10-03 | Christopher Ryan Cave Barrett | See Remarks | A | +175,000 deriv. | — |
| 2025-10-02 | Christian Angermayer | Director | C | +4,734,400 | — |
| 2025-08-18 | Apeiron Investment Group Ltd. | 10%+ Owner | Buy | +17,351,598 | +$38.00M |
| 2025-08-15 | Srinivas Rao | See Remarks | A | +868,571 deriv. | — |
| 2025-06-27 | Scott Braunstein | Director | A | +103,000 deriv. | — |
| 2025-06-27 | Andrea Heslin Smiley | Director | A | +103,000 deriv. | — |
| 2025-06-27 | Amir H Kalali | Director | A | +103,000 deriv. | — |
| 2025-06-27 | Laurent Fischer | Director | A | +103,000 deriv. | — |
| 2025-06-27 | Christian Angermayer | Director | A | +103,000 deriv. | — |
| 2025-06-27 | Sabrina Martucci Johnson | Director | A | +103,000 deriv. | — |
| 2025-06-27 | John Francis Hoffman | Director | A | +206,000 deriv. | — |
| 2025-06-04 | Christian Angermayer | Director | A | +131,698 deriv. | — |
| 2025-03-24 | Srinivas Rao | See Remarks | Sell | −75,418 | −$101.81K |
| 2025-03-24 | Sahil Kirpekar | Chief Business Officer | Sell | −48,563 | −$65.56K |
| 2025-03-24 | Anne Nagengast Johnson | Chief Financial Officer | Sell | −33,545 | −$45.29K |
| 2025-03-24 | Glenn Frank Short | Chief Scientific Officer | Sell | −13,161 | −$17.77K |
| 2025-03-24 | Apeiron Investment Group Ltd. | 10%+ Owner | Buy | +3,600,000 | +$5.04M |
| 2025-03-24 | Kevin James Craig | Chief Medical Officer | Sell | −11,563 | −$15.61K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christian Angermayer | Director | 53,412,414 | $392.58M |
| Cosmo Feilding-Mellen | Director | 7,702,990 | $56.62M |
| Sahil Kirpekar | Chief Business Officer | 115,636 | $849.92K |
| Robert Hershberg | Director | 100,000 | $735.00K |
| Gerd Kochendoerfer | Chief Operating Officer | 50,000 | $367.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATAI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.